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Abstract
Diamond Blackfan anemia (DBA) is a severe congenital failure of erythropoiesis. Despite
mutations in one of several ribosome protein genes, including RPS19, the cause of the erythroid
specificity is still a mystery. We hypothesize that because the chromatin of late erythroid cells
becomes condensed and transcriptionally inactive prior to enucleation, the rapidly proliferating
immature cells require very high ribosome synthetic rates. We measured RNA biogenesis in
primary mouse fetal liver erythroid progenitor cells; during the first 24 hours, cell number
increases 3–4 fold while, remarkably, RNA content increases 6-fold, suggesting an accumulation
of an excess of ribosomes during early erythropoiesis. Retrovirus infected siRNA RPS19
knockdown cells show reduced proliferation but normal differentiation, and cell cycle analysis
shows a G1/S phase delay. p53 protein is increased in the knockdown cells, and the mRNA level
for p21, a transcriptional target of p53, is increased. Furthermore, we show that RPS19
knockdown decreases MYB protein, and KIT mRNA is reduced, as is the amount of cell surface
KIT protein. Thus, in this shRNA murine model of DBA, RPS19 insufficient erythroid cells may
proliferate poorly because of p53 mediated cell cycle arrest, and also because of decreased
expression of the key erythroid signaling protein KIT.
Introduction
Diamond–Blackfan anemia (DBA) is a congenital anemia that develops at or soon after
birth. The anemia is due to failure of erythropoiesis, characterized by reticulocytopenia,
selective erythroid hypoplasia, and often by macrocytosis and high levels of red cell
adenosine deaminase activity. DBA is, however, a broad developmental disease, with
congenital abnormalities, particularly short stature, as well as facial, thumb and other
abnormalities in 35–47% patients (Ball, et al 1996, Ramenghi, et al 1999 Mar, Willig, et al
1999). DBA is inherited in about 40–45% of cases (Orfali, et al 2004), and genetic studies
have identified mutations in ribosomal protein (RP) genes; RPS19, in 25% of cases
(Draptchinskaia, et al 1999), RPS24 in 2% of cases (Gazda, et al 2006a), and RPS17 in one
case (Cmejla, et al 2007); recent data show evidence for involvement of at least three other
RP genes, RPL35a, RPL5 and RPL11 (Farrar, et al 2008, Gazda, et al 2008).
Cellular studies in patients have shown a deficiency of erythroid burst and colony-forming
units (BFU-Es and CFU-Es) (Freedman, et al 1976, Nathan, et al 1978), apoptosis of CFU-
Es after erythropoietin (EPO) deprivation (Perdahl, et al 1994), and defective expansion and
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differentiation in liquid culture (Ohene-Abuakwa, et al 2005). Importantly, normal
erythropoiesis after transplantation demonstrates that the defect is intrinsic to an erythroid
precursor. About 2/3 patients respond to treatment with steroids. Interestingly, and pertinent
to our studies, we and others have shown that DBA erythroid colony formation can be
corrected in many cases by KIT ligand (stem cell factor (SCF)) (Abkowitz, et al 1991,
Olivieri, et al 1991, Sieff, et al 1991).
In yeast and in mammalian cells, including patient cells, RPS19 deletion leads to a block in
ribosomal RNA biogenesis (Choesmel, et al 2007, Flygare, et al 2007) (Idol, et al 2007).
This important result has led to 2 main hypotheses; first, the block in ribosomal biogenesis
leads to nucleolar dysfunction and impaired cell division, and second, a reduction in
ribosomes decreases translation and leads to impaired protein synthesis.
A critical question is how haploinsufficiency of ribosomal proteins leads to failure of
erythropoiesis. Kinetic considerations may explain why erythroid cells are particularly
sensitive to ribosome protein deficiency. During fetal/early development rapid expansion of
the erythron requires high proliferation rates and high rates of ribosome synthesis. These
unique cells undergo chromatin condensation and enucleate, however, and therefore it is
reasonable to propose that translation capacity must be generated early to allow the shift to
globin synthesis when cells are becoming smaller and less able to make new ribosomes.
We used primary murine fetal liver erythroid cells to test this hypothesis. Our laboratory
developed a flow cytometry assay that allows quantitative evaluation of erythroid
differentiation in adult and neonatal hematopoietic tissues (Socolovsky, et al 2001). From
E12–E16, mouse fetal liver serves as the primary erythropoietic site for the embryo;
erythroid lineage cells comprise >90% of total fetal liver cells, and mouse fetal liver
provides a great resource to study erythropoiesis in primary cells. Mouse fetal liver cells
were used to develop a series of methods to monitor erythroid differentiation step-by-step
both in vivo and in vitro, purify large quantities of primary erythroid progenitors with a very
high purity, and culture purified erythroid progenitors in vitro to study their normal terminal
proliferation and differentiation. We used purified TER119-negative (Ter119−) cells from
fetal livers for our studies; TER119 is a glycophorin A associated protein that is expressed
on maturing erythroid cells. CFU-E and proerythroblasts comprise ~70–80% of the
TER119− population, which contains essentially no differentiated erythroid cells. These
purified E13.5 TER119− cells comprise ~3% B220- positive (CD45R) cells, ~1% CD3-
positive cells, essentially no Gr-1- positive (Ly-6G and Ly-6C (granulocytes and some
monocytes)) cells and ~9% Mac-1- positive (CD11b) cells. Over 90% of the TER119− cells
are KIT positive. The purified TER119− cells are cultured in fibronectin-coated plates in
medium with serum and EPO, which is removed from the medium after one day. After one
day in culture, early erythroblasts up-regulate the transferrin receptor (CD71) and some
differentiate into Ter119+ cells, but most are negative for benzidine (hemoglobin) staining.
At the end of two days, these cells further differentiate into benzidine-positive erythroblasts;
many of these cells lose their nuclei and form reticulocytes. During this two-day period the
number of erythroblasts increases 15–20 fold, corresponding to 4–5 cell divisions and
correlating well with the number of terminal cell divisions that a CFU-E goes through to
generate terminally differentiated erythrocytes (Gregory, et al 1974, Stephenson, et al 1971).
Thus, this culture condition supports both proper terminal proliferation and differentiation of
CFU-E progenitors.
We show that RNA synthesis of normal fetal liver progenitors is very rapid during the first
24 hours of culture, and exceeds the cell proliferation rate. Although it was shown many
years ago that the rate of RNA synthesis is related to cell proliferation rate, our observations
are novel in that RNA synthesis actually exceeds cell proliferation rate.
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To address the mechanism of erythroid failure in DBA we used small hairpin RNAs
(shRNAs) to knockdown Rps19 expression. We show that there is an early defect in cell
proliferation, but that differentiation of the residual cells is unimpaired, an observation
consistent with the normal differentiation of the surviving erythroid precursors in DBA.
To investigate the molecular mechanism of the erythroid failure we used a modified culture
system developed by Mullner, Beug and colleagues (Dolznig, et al 2005). Importantly, this
method of serum-free liquid culture in dexamethasone, insulin-like growth factor 1 (IGF-1)
and EPO allowed us to expand early erythroid cells for 5–6 days without terminal
differentiation. Using this system we show that cells deficient in RPS19 show stabilization
of p53 with an increase in p21 and G1 cell cycle delay, and also that MYB, a transcription
factor critically important for erythropoiesis, is reduced, leading to reduced expression of
one of its critical downstream erythroid transcriptional targets, KIT.
Thus we propose that DBA cells may be unable to produce sufficient RNA during early
stages of erythropoiesis, and that the block in ribosome biogenesis leads to nucleolar stress
and p53 mediated arrest or apoptosis, as well as a deficiency in KIT and impaired SCF
responsiveness.
Methods
Cells
The retrovirus-packaging cell line 293T was maintained in Dulbecco modified Eagle
medium (DMEM) containing 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA).
Fetal liver cells were isolated from E14.5 Balb/c (Jackson Laboratory, Bar Harbor, ME) or
C57BL embryos and mechanically dissociated by pipetting in erythroid-differentiation
medium (EDM) (Iscove modified Dulbecco medium [IMDM] containing 20% FBS, 2 mM
L-glutamine, and 10−4M β-mercaptoethanol). Single-cell suspensions were prepared by
passing the dissociated cells through 70 μm and 25 μm cell strainers. Nucleated cells were
counted.
Erythroid culture
When mouse fetal liver cells are double-labeled for erythroid-specific TER119 (Ikuta, et al
1990, Kina, et al 2000), a protein associated with glycophorin A, and non erythroid-specific
transferrin receptor (CD71) and analyzed by flow-cytometry, E14.5 fetal livers contain at
least five distinct populations of cells, defined by their characteristic staining patterns:
CD71medTER119low (R1), CD71highTER119low (R2), CD71highTER119high (R3),
CD71medTER119high (R4), and CD71lowTER119high (R5). The R1–R5 cells can be sorted
by FACS and further characterized by CFU-E colony assay, surface expression levels of
EPOR, and histological staining. R1 cells comprise ≥ 40% CFU-Es. (Zhang, et al 2003a),
R2 contain only a few CFU-Es and R3–R5 contain no erythroid progenitors. On average, R1
and R2 cells have ~1,900 cell surface EPOR/cell; later stages have many fewer receptors
(Zhang, et al 2003a). When R1–R5 cells are processed by May-Grunwald Giemsa stains,
their morphology resembles erythroblasts at different developmental stages (Fawcett 1997);
R5 cells have less than 10% the volume of R1 cells, consistent with 4 to 5 cell divisions
occurring during erythroid differentiation. The morphologic characteristics generally
corresponded to primitive progenitor cells and proerythroblasts in the R1 population,
proerythroblasts and early basophilic erythroblasts in R2, early and late basophilic
erythroblasts in R3, polychromatophilic and orthochromatophilic erythroblasts in R4, and
late orthochromatophilic erythroblasts and reticulocytes in the R5 population.
Purified TER119− cells fall mostly into the R1 and R2 windows, and when cultured in
serum containing medium with EPO proliferate and differentiate into R3, R4 and some R5
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cell compartments over a 48 hour culture period. Total fetal liver cells were labeled with
biotin-conjugated anti-TER119 antibody (1:100) (BD Pharmingen, San Diego, CA), and
TER119 negative (TER119−) cells were purified through a StemSep column as per the
manufacturer's instructions (StemCell Technologies, Vancouver, BC, Canada). Purified cells
were seeded in fibronectin-coated wells (BD Discovery Labware, Bedford, MA) at a cell
density of 1 × 105/mL. On the first day, the purified cells were cultured in Day 1 medium –
Iscove modified Dulbecco medium (IMDM) containing 15% fetal bovine serum (FBS), 1%
detoxified bovine serum albumin (BSA), 200 μg/mL holo-transferrin (Sigma, St Louis,
MO), 10 μg/mL recombinant human insulin (Sigma), 2 mM L-glutamine, 10−4 M β-
mercaptoethanol, and 2 U/mL EPO (Amgen, Thousand Oaks, CA). On the second day, this
medium was replaced with erythrocyte differentiation medium (EDM) – IMDM containing
20% FBS, 2 mM L-glutamine 10−4 M β-mercaptoethanol. Cells were counted at 24 and 48
hours and aliquots harvested for RNA and protein extraction. Total RNA was measured by
absorbance at 260 nm using a Nanodrop device.
A second culture system was introduced to allow amplification of R2 and R3 cells and to
measure the longer term effects of RPS19 knockdown. TER119− cells were cultured in
10−6M dexamethasone, 100 ng/mL SCF, 40 ng/mL IGF-1 and 2U/mL EPO in serum free
StemPro 34 medium (Dolznig, et al 2005). This culture system allows the amplification of
R2 cells with little differentiation into R3 Ter119+ cells over the 5–6 days required for these
experiments.
Retroviral constructs
MSCV-pgkGFP-U3-U6P-Bbs vector (murine stem cell retroviral vector-pgk promoter-GFP-
U6 promoter shRNA) was a gift from Dr. Biao Luo (Broad Institute, Cambridge MA). The
human U6 promoter was inserted at an NheI site in the U3 of the 3' LTR. The U6 promoter
is in the opposite orientation to the retroviral LTR. Two back-to-back BbsI sites were used
as cloning sites for 4 shRNAs selected to target Rps19.
Generation of retroviral supernatants and infection of primary cells
293T cells were seeded on 100-mm dishes 1 day before transfection. Then, 9 μg retroviral
plasmids together with 3μg pCL-Eco vector was used to cotransfect 293T cells with the
Lipofectamine Plus reagent (Invitrogen) according to the manufacturer's protocol. The
retroviral supernatants were collected 48 hours after transfection and stored in aliquots at
−80°C. To titer the packaged viruses, a series of dilutions of the supernatants were used to
infect NIH 3T3 cells; titers of 107 to 108 infectious units per milliliter were routinely
obtained. For infection of purified TER119− fetal liver cells, 1.2 × 104 to 5 × 105 cells were
resuspended in 1 mL thawed viral supernatant containing 10 μg/mL polybrene (Sigma) and
centrifuged at 2000 rpm for 1 hour at 37°C.
Immunostaining and flow cytometry analysis of erythroid differentiation
Freshly isolated fetal liver cells were immunostained with phycoerythrin (PE)–conjugated
anti-CD71 (1:200) (BD Pharmingen) and allophycocyanin (APC)–conjugated anti-Ter119
(1:200) (BD Pharmingen) antibodies, as previously described (Socolovsky, et al 2001).
Propidium iodide was added to exclude dead cells from analysis. GFP+ cells were sorted by
a FACS Moflo machine (Cytomation, Fort Collins, CO) with reduced pressure. Flow
cytometry was carried out on a FACS LSRII (BD Biosciences, Franklin Lakes, NJ).
Retrovirally transduced TER119− fetal liver cells were cultured in vitro for 6 days in serum-
free medium and then incubated at 37°C for 1 hour in the presence of 10 μg/mL Hoechst dye
33342 (Sigma). The cells were placed on ice and labeled with PE-anti-CD71 and APC-anti-
Ter119; all incubation and washing steps were carried out carefully at 4°C. Propidium
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iodide was added to exclude dead cells. Flow cytometry was carried out on an LSR II flow
cytometer (BD Biosciences). Collected data were analyzed by ModFit (Verity Software
House, Topsham, ME) or FloJo software (Tree Star Inc., Ashland, OR).
Quantitative Reverse Transcription Real Time-Polymerase Chain reaction (qRT-PCR)
For qRT-PCR an 18S rRNA fragment was cloned into the pCR2.1 TOPO vector and used in
a dose range 10−1–10−7 ng/well in triplicate with 18S primers and the SYBR green PCR
master mix (ABI). The slope and intercept of the standard curve was used to calculate the
RNA content of cDNA made from the unknown samples, which were assayed in triplicate or
quadruplicate.
Immunoblotting
For most experiments 1×106 cells were used to prepare protein extracts using RIPA buffer
supplemented with protease inhibitors. The boiled proteins were electrophoresed on 4–12%
Bis Tris NuPAGE precast gels (Invitrogen). The proteins were transferred to nitrocellulose
membrane and stained with Ponceau red to monitor transfer and loading, and then blocked
in 5% non-fat milk (NFM)/TBS-T. The membranes were incubated overnight in TBS-T with
or without 5% NFM in antibodies to MYB (Santa Cruz Biotechnology, Santa Cruz CA or
Upstate, Temecula, CA), p53 (Santa Cruz or Novocastra, Newcastle-upon-Tyne NCL-p53–
505), GAPDH (Santa Cruz), or RPS19 (Gazda, et al 2004), washed 3 × in TBS-T and
incubated for 1 hour at room temperature in the second detection antibody (anti-rabbit, anti-
mouse or anti-goat LI-COR fluorescent antibodies. The membrane was scanned on an
Odyssey Infrared Imaging System and the density of the bands determined.
Results
Early stages of fetal liver erythropoiesis are characterized by very rapid RNA synthesis
To explore the rate of RNA synthesis during erythropoiesis we enriched E14.5 fetal liver
cells for Ter119 negative (Ter119−) cells using biotinylated Ter119 and an
immunomagnetic column (StemSep). The cells were cultured on fibronectin coated plates in
EPO and serum-containing Day 1 medium supplemented with transferrin and insulin. After
24 hours the cells were centrifuged and resuspended in EDM (IMDM/20% FCS). Cells were
counted and total RNA extracted from an aliquot at 24 and 48 hours. Table 1 is an example
of an experiment in which the cell and RNA increase in the cultures is monitored. Cell
number increases very rapidly, and after 1 and 2 days there is a 4 and 28 fold increase in cell
number, representing 4–5 cell divisions. RNA extracted from these cells shows that the
greatest fold increase in RNA occurs during the first 24 hours of culture, and exceeds the
fold increase in cells. During the later stages of differentiation cell size decreases, RNA
yield per cell drops and therefore RNA level plateaus or even decreases slightly. Figure 1 is
a summary of 3 experiments showing the marked increase in total RNA (80% of which is
ribosomal) during the first 24 hours of culture, significantly greater than the fold increase in
cells.
Phenotypic consequences of Rps19 depletion in erythroid cells shRNA mediated Rps19
knockdown shows rapid Rps19 mRNA depletion
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) shows that after
retrovirus infection of TER119− cells with 4 different shRNAs to Rps19 there is rapid 70–
90% depletion of Rps19 mRNA by day 1, with further depletion by day 2 (Figure 2A).
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shRNA knockdown of RPS19 impairs proliferation of erythroid cells
To test the effect of shRNA mediated knockdown of RPS19 on cell proliferation of these
erythroid progenitors. cell counts were monitored at 24 and 48 hours (Figure 2B). Although
differences in cell number are not apparent on day 1, by day 2 there is a reduction in
proliferation of the knockdown cells. To determine the effect on of the knockdown on
RPS19 protein levels, we performed Western analysis with cells obtained on day 2; there is
a significant reduction in protein with the RPS19.1 knockdown construct that showed the
most pronounced reduction in mRNA, but the other constructs show only a small and
variable decrease in RPS19 protein by day 2 of culture (not shown).
shRNA knockdown of RPS19 does not affect erythroid differentiation
After purification the Ter119− fetal liver cells do not express Ter119 and are in the R1 and
R2 windows (not shown). After 2 days in culture the cells first express more CD71 and then
express Ter119 as they move into the R3 window. With further differentiation CD71 is lost
and cells move into the R4 and R5 regions (Zhang, et al 2003a). We next determined
whether knockdown of RPS19 affected differentiation. Although there are small differences
in the number of cells falling into the R2–R5 gates, there was no marked difference in the
differentiation capacity of knockdown compared with normal cells (Figure 2C). Thus, even
though the number of cells was reduced by RPS19 knockdown, the surviving cells could
differentiate normally.
G1 arrest in erythroblasts after siRNA knockdown of Rps19
Because the cells differentiate very quickly, by day 2, when the shRNAs are fully expressed,
the erythroblasts have already matured and are beginning to exit the cell cycle; this made it
difficult to monitor cell cycle status. Furthermore, reduction in RPS19 protein levels in the
rapidly proliferating serum cultures were not reproducible from experiment to experiment.
To obviate this problem we cultured Ter119− cells in serum-free conditions (StemPro34
medium with nutrients) supplemented with SCF, dexamethasone, IGF-1 and EPO. Under
these conditions CD71+, Ter119− (R2) cells can proliferate with little differentiation for up
to 14 days (Dolznig, et al 2005). In contrast to the work by Dolznig, Muellner and
colleagues we did not remove TER119+ cells at intervals during the culture, and therefore a
gradual increase in TER119+ cells was observed. To confirm that these cells are affected by
the shRNA knockdown of RPS19, Figure 3A shows growth curves indicating that the
RPS19 knockdown cells, similar to the serum containing cultures (Figure 2B, upper panel),
proliferate poorly in serum-free conditions; the lower panel confirms that the knockdown
cells proliferate more slowly compared to the few residual negative cells left in the culture
after FACS sorting on day 2, leading to a more rapid decline of GFP+ knockdown cells
compared with the non infected internal control cells or the GFP siLuciferase control. To
ensure that this culture system does model DBA, Figure 3B shows that the cellular level of
RPS19 protein is decreased to approximately 50% on day 6 of culture, normalized to the
control glycolytic enzyme GAPDH. To examine the cell cycle, day 6 erythroblasts were
incubated in Hoechst 33342 and cell cycle analysis performed on GFP, CD71, Ter119
positive cells that express either the control siLuciferase or the siRPS19.2 construct. Figure
3C shows that the RPS19 knockdown cells accumulate in G1 to a greater extent than the
GFP control cells. These data suggest that RPS19 knockdown is characterized by an
increase in G1 cells, consistent with the induction of a p53 response.
p53 is increased after siRPS19 knockdown
We next compared the levels of p53 in uninfected, GFP-luc and GFP-siRPS19 cells. Figure
4A shows that p53 protein levels are increased in the knockdown cells, and this is confirmed
by determining the p53/GAPDH ratio, normalized to the siLuciferase vector control in 3
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independent experiments (Figure 4B). Stabilization of p53 can lead to apoptosis or cell cycle
arrest. Figure 5A shows that the mRNA level of p21, a cyclin/cyclin dependent kinase
(CDK) inhibitor that is a known target of p53, is increased. In contrast, there is little change
in the level of p27, another cell cycle inhibitor that is not induced by p53. We did not find
evidence of apoptosis by annexin V staining in these cells (data not shown).
MYB is depleted after siRps19 knockdown
We have shown previously in human gene expression microarray studies that MYB is one of
the most highly under-expressed genes in DBA RPS19 mutant compared with normal
CD34+ cells (Gazda, et al 2006b). To determine whether the same is true of the RPS19
knockdown cells, we compared MYB protein by Western blot and found that MYB levels
are decreased in the knockdown cells (Figure 4A). Figure 4C shows the results of 3
independent experiments normalized to the siLuciferase vector control.
Two transcriptional targets of MYB are KIT and the glucocorticoid receptor. We found that
in comparison with GAPDH and HRPT housekeeping messages, which are unchanged in the
RPS19 knockdown cells, KIT mRNA levels are significantly reduced. In contrast, there is no
significant difference in glucocorticoid receptor mRNA levels (Figure 5B). We next
measured cell surface KIT (CD117) protein level by labeling cells with fluorescent
antibodies to CD117. Figure 6 shows that there is an siRPS19 induced reduction in cell
surface expression of KIT on day 6 of serum-free culture (note that this is a log scale) for
both the less differentiated TER119− and the more differentiated TER119+ cells.
Discussion
In this paper we ask why the erythroid lineage is selectively affected by RPS19 deficiency in
DBA. Our data raise two interesting possibilities that are not mutually exclusive. First,
during the first 24 hours of normal erythropoiesis, the rate of RNA production exceeds the
cell doubling rate. This indicates that these early erythroid precursors require very high rates
of RNA synthesis and may therefore be particularly sensitive to the block in ribosomal
biogenesis that is a feature of DBA cells. And second, we provide novel evidence in a
murine shRNA model of DBA that KIT, a critical regulator of erythropoiesis, is not
optimally expressed in cells that contain reduced amounts of RPS19.
To test RNA kinetics we measured RNA production in normal primary fetal liver erythroid
cells. In this system erythroid differentiation starts with the early committed erythroid
progenitor (the CFU-E), which expresses the highest level of EPO receptors and is critically
dependent on EPO, particularly for the early differentiation steps. This cell rapidly goes
through about 5 divisions in 48 hours as it matures. During the first 24 hours RNA
production exceeds the cell doubling rate. In contrast, during the next 24 hours, despite an
equally rapid cell proliferation rate, RNA production rate plateaus or declines (Table 1). It
was shown many years ago that RNA synthesis correlates with cell growth rate (Levine, et
al 1965,Todaro, et al 1965,Ward and Plagemann 1969). This regulation affects rRNA
synthesis, as cells placed in media with low or high concentrations of amino acids show low
or high incorporation of labeled precursors into RNA, respectively, which is blocked by
antibiotics that prevent rRNA synthesis (Franze-Fernandez and Pogo 1971). In contrast, our
data show that there is a discordance in RNA production during erythropoiesis; despite a
continuous rapid proliferation rate over 48 hours, the major phase of RNA production,
which contains ~80% ribosomal RNA, is at the earliest stage of erythropoiesis. This
suggests that these cells could be particularly sensitive to a block in ribosome biogenesis,
and is consistent with clinical laboratory descriptions in DBA patients of a block or absence
at the proerythroblast stage of differentiation.
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Our data are consistent with RNA and protein expression studies in murine erythroblasts that
show the highest levels of RPS19 in the most primitive cells (Da Costa, et al 2003). Human
microarray data confirm these findings at the RNA level and show that expression of RPS19
mRNA declines in freshly isolated human CD34 positive cells induced to differentiate over
2 weeks by stem cell factor and erythropoietin (Ebert, et al 2005). Furthermore, reduced
protein level in DBA patients with nonsense RPS19 mutations compared with normal
control cells was only detectable in CD34 positive bone marrow cells, but the reduction was
not demonstrable in DBA blood mononuclear cells (Gazda, et al 2004). An explanation for
this discrepancy might be that the differences are easier to detect in highly proliferative early
erythroid cells (contained in the CD34 fraction) compared with slowly proliferating longer
lived monocytes and lymphocytes in the mononuclear fraction that express much less
RPS19. Thus, we suggest that haploinsufficiency of RPS19 might be particularly limiting in
cell populations with high RPS19 expression, such as erythroid progenitors, which have an
enormous requirement for RNA and protein synthesis.
Our data show that the cell cycle is delayed but that the surviving cells differentiated
normally. We did not observe an increase in the number of apoptotic cells in the knockdown
cells (not shown). The data showing normal differentiation are consistent with observations
in patients, where surviving erythroid cells synthesize normal amounts of hemoglobin and
are not hypochromic. An increase in apoptotic cells has been described in DBA patient cells
and in cell lines by some (Farrar, et al 2008, Miyake, et al 2008, Perdahl, et al 1994) but not
by others (Kuramitsu, et al 2008), and an increase in apoptotic cells has been observed in the
bone marrow cells of a dark skinned mouse with a mutation in Rps19 and a very mild
erythroid phenotype (McGowan, et al 2008). It is possible that apoptosis or cell cycle arrest
depend on the degree of ribosomal stress and the effect on p53, and our studies in primary
knockdown cells, which have a limited time course for experimentation, may not allow
sufficient time for apoptosis to become evident.
To explore the molecular mechanism by which lack of ribosome proteins could trigger cell
cycle arrest and apoptosis, we used a serum-free culture system that allows expansion of
primitive erythroid progenitors in dexamethasone, SCF, erythropoietin and IGF-1 (Dolznig,
et al 2005). This modification of the culture system allows one to evaluate the effect of
RPS19 knockdown on the cell cycle as well as gene and protein expression associated with
such a knockdown. Cell cycle analysis shows a G1/S phase block, suggesting a delay in the
cell cycle. The oncoprotein MDM2 is a crucial regulator of the tumor suppressor p53,
targeting it for ubiquitin-mediated destruction (Haupt, et al 1997, Honda, et al 1997, Oliner,
et al 1993). Nucleolar or ribosomal stress-associated pathways can be activated to sequester
MDM2 and thereby stabilize p53 (Pestov, et al 2001, Rubbi and Milner 2003), and the free
ribosomal proteins L5, L11 and L23 can mediate this process by binding to MDM2 (Dai and
Lu 2004, Jin, et al 2004, Lohrum, et al 2003, Marechal, et al 1994, Zhang, et al 2003b). We
found that p53 is increased in RPS19 knockdown cells and that a transcriptional target of
p53 that inhibits cyclin/CDK and the cell cycle, p21, is increased. Although p53 levels are
increased the increase is modest
We showed previously in gene expression microarray studies that in comparison with
normal CD34+ cells, MYB message levels are much lower in DBA RPS19 mutant cells
(Gazda, et al 2006b). Embryonic erythropoiesis in Myb knockout mice is normal, but there
is complete failure of definitive erythropoiesis in fetal liver.(Mucenski, et al 1991)
Progenitors of other lineages, but not megakaryocytes, were also decreased, indicating that
MYB is required for early definitive cellular expansion. Furthermore, a knockdown allele of
Myb shows that suboptimal levels of MYB favor macrophage and megakaryocyte
differentiation while higher levels are particularly important for erythropoiesis and
lymphopoiesis (Emambokus, et al 2003). Moreover, in primary murine fetal liver erythroid
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cells, study of Myb hypomorphs showed that MYB is a critical regulator of KIT expression
(Vegiopoulos, et al 2006). There is evidence in chicken and mouse cells that Myb
transcription is regulated by glucocorticoids (Ganguli, et al 2002, Wessely, et al 1997), and
this may contribute to the potent role of glucocorticoids in the dexamethasone mediated
proliferation and blocked differentiation of immature erythroid progenitors.(Dolznig, et al
2001) Interestingly, MYB interacts physically with nucleolin, a nucleolar protein important
in rRNA biogenesis; it is translocated from the nucleolus after nucleolar stress induced by
heat shock or ionizing radiation, and nucleolin binds to MYB and inhibits its transcriptional
activity (Daniely, et al 2002, Ying, et al 2000).
Here we show that, like DBA patient cells, MYB protein is decreased after shRNA mediated
knockdown of RPS19. Furthermore, KIT, a transcriptional target of MYB, is reduced at the
mRNA and protein levels. Support for a role of KIT comes from studies of the dark skin
mice and parallel studies done in Rps6 conditional loxP mice (McGowan, et al 2008,
Volarevic, et al 2000). The dark skin in the Rps19 mutant mice appears to result from an
indirect SCF-mediated effect on melanocytes in the epidermis, and this phenotype is
recapitulated by hemizygosity of Rps6 in keratinocytes (McGowan, et al 2008). However,
both the dark skin Dsk3 (Rps19) or Dsk4 (Rps20) mutant mice and deletion of Rps6 in
melanocytes show a reduction in the number and/or proliferative capacity of melanocytes;
this results in lighter skin and impaired migration of melanocytes, with a white belly spot in
10% of the Dsk3 animals that is reminiscent of the white spot in mice with Kit mutations;
indeed, the size of the white spot is enhanced when placed on a KitWv genetic background
(McGowan, et al 2008).
In conclusion, we propose that the erythroid defect in DBA results from an inability of early
erythroid progenitors to make sufficient ribosomal RNA due to a block in ribosome
biogenesis; these early progenitors are particularly susceptible to deficiency of ribosomal
proteins as their rate of ribosomal biogenesis is very rapid. This is accompanied by nucleolar
stress with p53 stabilization and depletion of a critical erythroid transcription factor MYB,
which results in impaired expression of KIT.
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Figure 1.
Ter119− fetal liver cells cultured in serum with EPO and transferrin. At 24 hours cell
number and total RNA content were measured. N=3, mean +/− 2SD.
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Figure 2.
A, purified Ter119 negative fetal liver cells were infected with empty vector or one of 4
shRNA retrovirus constructs designed to knockdown Rps19. At 24 and 48 hours after
infection the RNA was extracted and Rps19 mRNA measured by quantitatitive RT-PCR, B,
counted, and C, incubated at 48 hours with PE- CD71 and APC-Ter119.
Sieff et al. Page 14
Br J Haematol. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sieff et al. Page 15
Br J Haematol. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
A, serum free cultures of Ter119− fetal liver cells were monitored daily for cell number
(upper panel) and the proportion of GFP+ cells (lower panel) after infection with vector or
Rps19 shRNA contructs on day 0 and sorting of positive cells on day 2. B, Western blot of
control (siLuciferase) and siRps19 infected cells cultured for 6 days in serum-free conditions
and sorted for GFP immediately before lysis. The lower histogram shows the normalized
RPS19:GAPDH ratio with standard deviation (n=2) C. Cell cycle analysis of day 6 serum-
free cultured erythroblasts after staining with Hoechst 33142 for 1 hour and labeled with
CD71 and Ter119. Representative example of 2 experiments.
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Figure 4.
A, Ter119− fetal liver cells cultured without (control) or following infection with
siLuciferase (GFP) or siRps19 for 6 days; Western analysis of protein expression using
antibodies to p53, c-Myb or GAPDH. B, normalized ratio of p53:GAPDH, showing a
modest 20% increase in p53 in siRPS19.2 compared with the siLuciferase empty vector
control (n=3). C, normalized ratio of MYB:GAPDH, showing a marked decrease in MYB in
siRPS19.2 compared with the siLuciferase control (n=3).
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Figure 5.
Control or siRNA Rps19 infected Ter119− fetal liver cells cultured for 6 days in serum free
conditions and FACS sorted before analysis of mRNA levels by quantitative RT-PCR. A,
HPRT (control) RPS19, p21 and p27. B, HPRT and GAPDH (controls), globin (Hbb), c-Kit
and glucocorticoid receptor (GR).
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Figure 6.
Purified Ter119− fetal liver cells were infected with siLuciferase conrol (GFP) or an shRNA
retrovirus construct designed to knockdown Rps19 (RP2). On day 6 the cells were labeled
with antibodies to CD71, Ter119 and CD117 (c-Kit) and the GFP+ cells analyzed for
differentiation stage (upper panels) and c-Kit expression (lower panel). The results show
decreased KIT expression in siRPS19.2 compared with siLuciferase control for both the less
differentiated TER119− gate (mean fluorescence values 2394 and 3521, respectively) and
the more differentiated TER119+ gate (mean fluorescence values 3893 and 4144,
respectively). Representative example of 2 experiments.
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Table 1
The TER119− Day 0 cells fall into the R1/R2 window (see methods)
# Parameter Day 0 Day 1 Day 2
1 Cell # (×106) 2 8.3 57.6
2 Fold Increase in Cells 1 4.15 28.8
3 RNA/Cell (pg) 2.59 3.84 0.44
4 Total RNA in Culture (μg) 5.2 31.9 25.3
5 Fold Increase in RNA 1 6.13 4.87
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